Biopolym. Cell. 2019; 35(4):303-312.
http://dx.doi.org/10.7124/bc.000A0B
Structure and Function of Biopolymers
Generation and characterization of the MCF-7 cell line with a knockout of a p85-S6K1 isoform of the ribosomal protein S6 kinase 1
1Holiar V. V., 1Gotsulyak N. Ya., 1Khoruzhenko A. I., 1Zaiets I. V.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143

Abstract

Aim. To generate the p85-S6K1 knockout MCF-7 breast cancer cell line and to evaluate the effect of p85-S6K1 on cell growth, migration and survival under stress conditions. Methods. CRISPR/Cas9 genome editing, Western blotting, immunofluorescence staining, MTT assay, in vitro scratch assay. Results. We generated two clones of the p85-S6K1 knockout MCF-7 cell line and tested their survival upon hydrogen peroxide treatment as well as the proliferation and migration rates. The generated cell clones display an impaired ability to survive under oxidative stress, exhibit inhibition of cell growth, cell motility and downregulation of rpS6 phosphorylation on Ser235/236/240/244 under cell starvation compared to the control cells. Conclusions. The p85-S6K1 isoform could be involved in modulation of cancer cell behaviour promoting cell growth, migration and survival. The obtained clones can be further used to study the participation of different S6K1 isoforms in the control of cell function.
Keywords: mTOR/S6K1 signaling, CRISPR/Cas9, p85-S6K1 isoform.
Full text: (PDF, in English)

References

[1] Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155-62.
[2] Tavares MR, Pavan IC, Amaral CL, Meneguello L, Luchessi AD, Simabuco FM. The S6K protein family in health and disease. Life Sci. 2015;131:1-10.
[3] Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012;441(1):1-21.
[4] Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med. 2007;13(6):252-9.
[5] Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886-918. doi: 10.3390/ijms13021886.
[6] Lyzogubov V, Khozhaenko Y, Usenko V, Antonjuk S, Ovcharenko G, Tikhonkova I, Filonenko V. Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Exp Oncol. 2005;27(2):141-4.
[7] Lyzogubov VV, Lytvyn DI, Dudchenko TM, Lubchenko NV, Pogrybniy PV, Nespryadko SV, Vinnitska AB, Usenko VS, Gout IT, Filonenko VV. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas. Exp Oncol. 2004;26(4):287-93.
[8] Lytvyn DI, Dudchenko TM, Lyzogubov VV, Usenko VS, Nespryadko SV, Vinnitskaya AB, Vorobyova LI, Pal'chevskiy SS, Filonenko VV, Pogrebnoy PV. Expression of α- and β-isoforms of p70S6 kinase in human endometrial tumors. Exp Oncol. 2003; 25(4):274-8.
[9] Lyzogubov VV, Usenko VS, Khojaenko YuS, Lytvyn DI, Soldatkina MA, Rodnin NV, Filonenko VV, Pogribniy PV. Immunohistochemical analysis of p70S6 kinase α in human thyroid tissue upon pathology. Exp Oncol. 2003; 25(4):304-6.
[10] Holz MK. The role of S6K1 in ER-positive breast cancer. Cell Cycle. 2012;11(17):3159-65.
[11] Liu J, Li HQ, Zhou FX, Yu JW, Sun L, Han ZH. Targeting the mTOR pathway in breast cancer. Tumour Biol. 2017;39(6):1010428317710825.
[12] Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat. 2003;78(3):313-22.
[13] Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L, Stål O. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat. 2011;128(3):713-23.
[14] Grove JR, Banerjee P, Balasubramanyam A, Coffer PJ, Price DJ, Avruch J, Woodgett JR. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini. Mol Cell Biol. 1991;11(11):5541-50.
[15] Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009;27(1):12-21.
[16] Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14(3):185-93.
[17] Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, Karni R. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 2013;3(1):103-15.
[18] Zhang J, Guo J, Qin X, Wang B, Zhang L, Wang Y, Gan W, Pandolfi PP, Chen W, Wei W. The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth. Sci Signal. 2018;11(523).
[19] Savinska LO, Kijamova RG, Pogrebnoy PV, Ovtsharenko GV, Gout IT, Filonenko VV. Comparative characterization of S6 kinase α and β isoforms expression in mammalian tissues. Biopolym Cell. 2001; 17(5):374-9.
[20] Savinska LO, Klipa OM, Khoruzenko AI, Shkarina KA, Garifulin OM, Filonenko VV. Generation and characterization of polyclonal antibodies specific to N-terminal extension of p85 isoform of ribosomal protein S6 kinase 1 (p85 S6K1). Biopolym Cell. 2015; 31(4):294-300.
[21] Jia CH, Li M, Liu J, Zhao L, Lin J, Lai PL, Zhou X, Zhang Y, Chen ZG, Li HY, Liu AL, Yang CL, Gao TM, Jiang Y, Bai XC. IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1. Cell Death Differ. 2013;20(2):248-58.
[22] Comşa Ş, Cîmpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res. 2015;35(6):3147-54.
[23] Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 2006;24(2):185-97.
[24] Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene. 2006;25(53):7029-40.
[25] Kyou Kwon J, Kim SJ, Hoon Kim J, Mee Lee K, Ho Chang I. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer. Urol Oncol. 2014;32(1):51.e27-35. doi: 10.1016/j.urolonc.2013.08.005.
[26] Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014;6(4):361-76.
[27] Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A, Cagnard N, Carpentier W, Kiss T, Meyuhas O, Pende M. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene. 2014;33(4):474-83.
[28] Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747-58.
[29] Pardo OE, Seckl MJ. S6K2: The Neglected S6 Kinase Family Member. Front Oncol. 2013;3:191. doi: 10.3389/fonc.2013.00191. eCollection 2013.
[30] Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213-23.
[31] Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26(13):1932-40.